Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one or more psychiatric disorders and a cumulative lifetime exposure to antipsychotic medication of three months or more.
Study Type
OBSERVATIONAL
Enrollment
70
Customized clinician-reported outcomes
Clinician evaluation of patient burden due to tardive dyskinesia symptoms
Time frame: 12 months
EuroQOL 5 Dimensions EQ-5D-5L)
General, single index measure for describing and valuing health-related quality of life.
Time frame: 12 months
Customized caregiver-reported outcomes:
Caregiver evaluation of perceived burden of symptoms on patients as well as the impact on the caregiver
Time frame: 12 months
Sheehan Disability Scale (SDS)
Assessment of functional impairment and disability
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Neurocrine Clinical Site
Little Rock, Arkansas, United States
RECRUITINGNeurocrine Clinical Site
Anaheim, California, United States
RECRUITINGNeurocrine Clinical Site
Anaheim, California, United States
RECRUITINGNeurocrine Clinical Site
Long Beach, California, United States
RECRUITINGNeurocrine Clinical Site
Los Gatos, California, United States
RECRUITINGNeurocrine Clinical Site
Oceanside, California, United States
RECRUITINGNeurocrine Clinical Site
Gainesville, Florida, United States
RECRUITINGNeurocrine Clinical Site
Hialeah, Florida, United States
RECRUITINGNeurocrine Clinical Site
Jacksonville, Florida, United States
RECRUITINGNeurocrine Clinical Site
Miami, Florida, United States
RECRUITING...and 24 more locations